辛伐他汀对冠心病患者PCI术后高敏C反应蛋白的影响

Effects of Simvastatin on Blood hs-CRP Levels in Patients with CHD after Percutaneous Coronary Intervention

目的观察口服辛伐他汀对冠心病患者介入治疗后高敏C反应蛋白的影响。方法入选冠心病拟PC I治疗的患者74例,随机分为辛伐他汀组(n=37例)和对照组(n=37例),辛伐他汀组患者术前在标准治疗基础上口服辛伐他汀40mg/d共1周,对照组除未服辛伐他汀外其他治疗均与辛伐他汀组相同,两组患者分别于术前、术后5天每天采集空腹静脉血3m l,对高敏C反应蛋白进行定量分析。结果PC I术后两组高敏C反应蛋白均显著升高(P<0.05),辛伐他汀组高敏C反应蛋白升高幅度显著低于对照组(P<0.05)。结论冠心病患者PC I术前口服辛伐他汀可显著减低PC I术后高敏C反应蛋白的升高。

Objective To investigate the effects of Simvastatin on blood levels of hs - CRP after percutaneous coronary intervention. Methods Seventy - fourh patients with CHD were enrolled in the study. Patients scheduled for elective coronary intervention were assigned to Simvastatin （40 mg/d, n = 37） or placebo （ n = 37） 7 days before the procedure according to in - hospital sequence. The hs -CRP levels were measured at baseline and at 1 st,2nd,4th,5th, 7th days after the procedure. ResuLts Detection of hs - CRP was significantly higher after the procedure compared with baseline. Conclusion Pretreatment with Simvastatin 40mg/d for 7 days significantly reduce postoperative hs - CRP in elective coronary intervention.